Table 2.
Ongoing clinical studies
| Country | Study type | Phase | n | Primary objective |
|---|---|---|---|---|
| Nigeria |
Sickle cell proguanil vs AS+MQ vs SP+AQ |
1/2 |
270 |
Safety and tolerability of bi-monthly intermittent preventive treatment with AS+MQ or sulphadoxine-pyrimethamine + amodiaquine compared to proguanil for prevention of malaria and related complications in patients with sickle cell anaemia |
| Amazon Basin |
Efficacy |
2/3 |
100 |
Evaluate the effectiveness of ASMQ FDC to treat uncomplicated falciparum malaria in the Juruá Valley |
| Burkina Faso |
Pregnant women |
2/3 |
48 |
PK of ASMQ FDC in pregnant women |
| Burkina Faso, Ghana, Malawi and Zambia |
Pregnant women: ASMQ vs DHA-PQ vs ASAQ vs AL |
3 |
3500 |
Efficacy and safety of four ACTs (artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate and dihydroartemisinin-piperaquine) in pregnant women with P. falciparum malaria |
| Tanzania, Burkina Faso and Kenya |
Efficacy, safety and PK in children ASMQ vs AL |
4 |
940 |
Efficacy, safety and population pharmacokinetics ASMQ FDC in African children vs artemether-lumefantrine |
| Thailand |
Pregnant women: ASMQ vs DHA-PQ vs AL |
3 |
1,000 |
Randomized trial of three ACT for malaria in pregnancy (DMA) |
| Brazil | Efficacy and safety P. vivax: ASMQ+PQ vs CQ+PQ vs AL+PQ | 3 | 264 | Efficacy and safety for treating P. vivax: ASMQ+PQ vs CQ+PQ vs AL+PQ |